NDAINTRAVENOUSINJECTABLEPriority Review
Approved
Mar 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Priority Review
FLUORESCITE (fluorescein sodium) by Alcon is 12. First approved in 2006.
Drug data last refreshed 7m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FLUORESCITE (fluorescein sodium) is an intravenous diagnostic dye used in ophthalmology to visualize retinal and choroidal vasculature during fundus imaging. The drug fluoresces when exposed to blue light (465-490 nm wavelengths), emitting yellowish-green light (520-530 nm) that is captured by fundus cameras to assess vascular integrity and perfusion. It is an essential tool for diagnosing diabetic retinopathy, macular degeneration, retinal detachment, and other ocular vascular conditions.
LOE Approaching
As LOE approaches, the FLUORESCITE brand team is likely consolidating resources and focusing on retention strategies in a mature, specialty diagnostic market with limited growth.
Mechanism of Action
12.1 Mechanism of Action Fluorescein sodium responds to electromagnetic radiation and light between the wavelengths of 465-490 nm and fluoresces, i.e., emits light at wavelengths of 520-530 nm. Thus, the hydrocarbon is excited by blue light and emits light that appears yellowish-green. Following…
Indications
Worked on FLUORESCITE at Alcon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.